Earlier this year NDA released its 2016 annual report on drug approvals in both the EU and the US. One striking finding: US approvals (NMEs) plummeted from 45 (2015) to 19 — a drop of almost 60 percent.
That dramatic number wasn’t the only thing that caught our attention though. When we drilled down into all the applications, we spotted some important trends that you can read about in this article written by Christine Chirdo – Service Area Lead: High Stakes Meetings.
You will also learn how we can support you with key activities to make your high-stakes meetings a success. Prepare to Win.
Christine Chirdo – Service Area Lead: High Stakes Meetings, NDA Group/PharmApprove